^
    5ms
    COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=48, Completed, Compugen Ltd | Active, not recruiting --> Completed | N=100 --> 48
    Trial completion • Enrollment change • Combination therapy • Metastases
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)
    9ms
    A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=101, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | N=241 --> 101 | Trial completion date: Feb 2025 --> Jan 2024
    Trial completion • Enrollment change • Trial completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • renvistobart (BMS-986207)
    10ms
    A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=1, Completed, Bristol-Myers Squibb | Terminated --> Completed
    Trial completion
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • renvistobart (BMS-986207)
    10ms
    COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=100, Active, not recruiting, Compugen Ltd | Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Dec 2023 --> May 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)
    over1year
    A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=241, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Aug 2024 --> Feb 2025 | Trial primary completion date: Aug 2024 --> Mar 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • renvistobart (BMS-986207)
    over1year
    A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=241, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Feb 2025 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • renvistobart (BMS-986207)
    almost2years
    Durable responses following anti-TIGIT (BMS-986207) and anti-LAG3 (BMS-980616) in combination with pomalidomide in relapsed myeloma: MMRF MyCheckpoint trial (AACR 2023)
    Anti-LAG-3 and anti-TIGIT mAb alone and in combination with Pom are safe, feasible and clinically active in relapsed MM after Pom and anti-CD38 mAb. These data provide the first evidence of clinical activity of TIGIT and LAG-3 blockade in MM. Translational results utilizing serial analyses with mass cytometry suggest evidence of immune activation following combination therapy.
    Combination therapy
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    pomalidomide • renvistobart (BMS-986207)
    almost2years
    COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=100, Active, not recruiting, Compugen Ltd | Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2023 --> Dec 2023
    Enrollment closed • Trial primary completion date • Combination therapy • Metastases
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)
    almost2years
    A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=241, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • renvistobart (BMS-986207)
    over2years
    COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Compugen Ltd | Trial primary completion date: Aug 2022 --> Jan 2023
    Trial primary completion date • Combination therapy
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)
    over2years
    A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=241, Recruiting, Bristol-Myers Squibb | Trial completion date: Feb 2026 --> Feb 2025
    Trial completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • renvistobart (BMS-986207)
    over2years
    A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=241, Recruiting, Bristol-Myers Squibb | N=130 --> 241 | Trial completion date: Jun 2025 --> Feb 2026 | Trial primary completion date: Jun 2025 --> Mar 2024
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • renvistobart (BMS-986207)
    3years
    COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab - preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (NCT04570839) (SITC 2021)
    Data cutoff 28 Jun 2021. Trial Registration NCT04570839
    Clinical • PK/PD data • Combination therapy
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)